Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, December 30th:
CoreCard Corporation CCRD: This technology solutions and processing services company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7% over the last 60 days.
CoreCard Corporation price-consensus-chart | CoreCard Corporation Quote
CoreCard’s shares gained 44.9% over the last three months compared with the S&P 500’s advance of 5.3%. The company possesses a Momentum Score of A.
CoreCard Corporation price | CoreCard Corporation Quote
Entrada Therapeutics, Inc. TRDA: This clinical-stage biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 64.7% over the last 60 days.
Entrada Therapeutics, Inc. price-consensus-chart | Entrada Therapeutics, Inc. Quote
Entrada’s shares gained 8.8% over the last three months compared with the S&P 500’s advance of 5.3%. The company possesses a Momentum Score of A.
Entrada Therapeutics, Inc. price | Entrada Therapeutics, Inc. Quote
NRx Pharmaceuticals, Inc. NRXP: This clinical-stage biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 46.2% over the last 60 days.
NRx Pharmaceuticals, Inc. price-consensus-chart | NRx Pharmaceuticals, Inc. Quote
NRx’s shares gained 11.8% over the past month compared with the S&P 500’s decline of 0.7%. The company possesses a Momentum Score of A.
NRx Pharmaceuticals, Inc. price | NRx Pharmaceuticals, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NRx Pharmaceuticals, Inc. (NRXP) : Free Stock Analysis Report
Entrada Therapeutics, Inc. (TRDA) : Free Stock Analysis Report
CoreCard Corporation (CCRD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.